Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Autonomic nervous system: an integrative regulator in circadian rhythm of blood pressure.

Frontiers in neurology·2026
Same author

Identifying risk factors for adverse drug reactions in HIV/AIDS patients using LASSO regression modeling.

BMC infectious diseases·2026
Same author

PIP<sub>2</sub> activation of the cardiac I<sub>Ks</sub> potassium channel.

Nature communications·2026
Same author

Chronic papillary conjunctivitis as a novel ocular manifestation of Rickettsia felis infection: A case report.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2026
Same author

Quantitative proteomics unravels root-specific response mechanisms and phytotoxicity of four typical UV filters in pakchoi (Brassica rapa L. ssp. chinensis).

Plant physiology and biochemistry : PPB·2026
Same author

Necessity and safety of primary closure of the patent processus vaginalis in laparoscopic orchiopexy: protocol for systematic review and meta-analysis.

BMJ open·2026

相关实验视频

Updated: Jul 6, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

氧化合成酶-2二聚化选择性抑制剂对急性心脏全移植排斥的作用

Matthias J Szabolcs1, Ji Sun, Ningsheng Ma

  • 1Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

Circulation
|October 31, 2002
PubMed
概括

在老鼠中,选择性抑制氧化合成酶-2 (NOS2) 分解显著延长了心脏全移植的存活时间,并减少了炎症和心肌细胞损伤,提供了一个有前途的治疗策略.

更多相关视频

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

相关实验视频

Last Updated: Jul 6, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
10:05

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition
08:38

A Neonatal Heterotopic Rat Heart Transplantation Model for the Study of Endothelial-to-Mesenchymal Transition

Published on: July 21, 2023

科学领域:

  • 免疫学 免疫学 免疫学
  • 心脏病学 心脏病学
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 氧化合成酶-2 (NOS2) 与急性心脏全移植排斥有关,导致炎症,功能障碍和心肌细胞死亡.
  • 针对NOS2单体二分化的新型全抑制剂已经开发出来,以阻止其活性.

研究的目的:

  • 为了研究选择性NOS2抑制在老鼠心脏全移植排斥模型中的治疗潜力.
  • 评估NOS2阻断对全移植存活,炎症和心肌细胞完整性的影响.

主要方法:

  • 接受异型心脏移植的老鼠接受了NOS2抑制剂 (BBS-1或BBS-2) 或对照组的治疗.
  • 评估了心脏杂种移植的存活率,NOx合成,炎症细胞透,,心肌细胞损伤和亡细胞计数.

主要成果:

  • 用NOS2抑制剂治疗显著增加了心脏全移植存活率 (13.3-14.2天与对照组中的6.8天相比).
  • 抑制NOS2降低了NOx合成的53%,炎症细胞透,和心肌细胞损伤.
  • 免疫染揭示了NOS2表达减少,甲酸氨酸和治疗的异位移植中的亡.

结论:

  • 选择性抑制NOS2二分化有效延长心脏全移植的存活时间.
  • NOS2阻塞减轻心肌炎症,并减少心肌细胞损伤在急性心脏异位移植排斥期间.